ID   PTK6_HUMAN              Reviewed;         451 AA.
AC   Q13882; B2RCR3; B4DW46; Q58F01;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-APR-2017, entry version 181.
DE   RecName: Full=Protein-tyrosine kinase 6;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680};
DE   AltName: Full=Breast tumor kinase;
DE   AltName: Full=Tyrosine-protein kinase BRK;
GN   Name=PTK6; Synonyms=BRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary tumor;
RX   PubMed=8036022;
RA   Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N.,
RA   Page M.J., Gusterson B.A., Crompton M.R.;
RT   "Cloning and characterisation of cDNAs encoding a novel non-receptor
RT   tyrosine kinase, brk, expressed in human breast tumours.";
RL   Oncogene 9:2383-2390(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=9333026; DOI=10.1038/sj.onc.1201292;
RA   Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.;
RT   "Characterisation and chromosome mapping of the human non receptor
RT   tyrosine kinase gene, brk.";
RL   Oncogene 15:1497-1502(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Melanocyte;
RX   PubMed=9749526;
RA   Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.;
RT   "Exon-intron structure of the human PTK6 gene demonstrates that PTK6
RT   constitutes a distinct family of non-receptor tyrosine kinase.";
RL   Mol. Cells 8:401-407(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219
RP   AND TYR-447.
RX   PubMed=8940083; DOI=10.1074/jbc.271.48.30956;
RA   Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E.,
RA   Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.;
RT   "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase,
RT   sensitizes mammary epithelial cells to epidermal growth factor.";
RL   J. Biol. Chem. 271:30956-30963(1996).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=9185712;
RX   DOI=10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F;
RA   Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A.,
RA   Bennett D.C.;
RT   "Loss of expression of receptor tyrosine kinase family genes PTK7 and
RT   SEK in metastatic melanoma.";
RL   Int. J. Cancer 71:1061-1065(1997).
RN   [9]
RP   FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66;
RP   ARG-105 AND LYS-219.
RX   PubMed=10980601; DOI=10.1038/sj.onc.1203775;
RA   Mitchell P.J., Sara E.A., Crompton M.R.;
RT   "A novel adaptor-like protein which is a substrate for the non-
RT   receptor tyrosine kinase, BRK.";
RL   Oncogene 19:4273-4282(2000).
RN   [10]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH
RP   KHDRBS1.
RX   PubMed=10913193; DOI=10.1128/MCB.20.16.6114-6126.2000;
RA   Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V.,
RA   Cochrane A.W., Chen T., Tyner A.L.;
RT   "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively
RT   regulates its RNA binding ability.";
RL   Mol. Cell. Biol. 20:6114-6126(2000).
RN   [11]
RP   PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND
RP   TYR-351, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   MUTAGENESIS OF TYR-342 AND TYR-447, ENZYME REGULATION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12121988; DOI=10.1074/jbc.M203877200;
RA   Qiu H., Miller W.T.;
RT   "Regulation of the nonreceptor tyrosine kinase Brk by
RT   autophosphorylation and by autoinhibition.";
RL   J. Biol. Chem. 277:34634-34641(2002).
RN   [12]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12833144; DOI=10.1038/sj.onc.1206465;
RA   Derry J.J., Prins G.S., Ray V., Tyner A.L.;
RT   "Altered localization and activity of the intracellular tyrosine
RT   kinase BRK/Sik in prostate tumor cells.";
RL   Oncogene 22:4212-4220(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447,
RP   AND PHOSPHORYLATION.
RX   PubMed=15471878; DOI=10.1074/jbc.M409579200;
RA   Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.;
RT   "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the
RT   RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and
RT   SLM-2.";
RL   J. Biol. Chem. 279:54398-54404(2004).
RN   [14]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PXN.
RX   PubMed=15572663; DOI=10.1128/MCB.24.24.10558-10572.2004;
RA   Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.;
RT   "Brk activates rac1 and promotes cell migration and invasion by
RT   phosphorylating paxillin.";
RL   Mol. Cell. Biol. 24:10558-10572(2004).
RN   [15]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010;
RA   Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.;
RT   "Differential expression of the non-receptor tyrosine kinase BRK in
RT   oral squamous cell carcinoma and normal oral epithelium.";
RL   Oral Oncol. 40:1040-1047(2004).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK.
RX   PubMed=15539407; DOI=10.1074/jbc.M412038200;
RA   Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D.,
RA   Lange C.A.;
RT   "Regulated association of protein kinase B/Akt with breast tumor
RT   kinase.";
RL   J. Biol. Chem. 280:1982-1991(2005).
RN   [17]
RP   MUTAGENESIS OF TRP-184, AND ENZYME REGULATION.
RX   PubMed=15961400; DOI=10.1074/jbc.M504568200;
RA   Kim H.I.E., Lee S.T.;
RT   "An intramolecular interaction between SH2-kinase linker and kinase
RT   domain is essential for the catalytic activity of protein-tyrosine
RT   kinase-6.";
RL   J. Biol. Chem. 280:28973-28980(2005).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF KHDRBS1.
RX   PubMed=16179349; DOI=10.1074/jbc.M505802200;
RA   Lukong K.E., Larocque D., Tyner A.L., Richard S.;
RT   "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates
RT   intranuclear localization and cell cycle progression.";
RL   J. Biol. Chem. 280:38639-38647(2005).
RN   [19]
RP   INTERACTION WITH IRS4, AND ENZYME REGULATION.
RX   PubMed=15870689; DOI=10.1038/sj.onc.1208721;
RA   Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.;
RT   "Interaction between Brk kinase and insulin receptor substrate-4.";
RL   Oncogene 24:5656-5664(2005).
RN   [20]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=16651629; DOI=10.2353/ajpath.2006.050521;
RA   Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M.,
RA   Zhang Q., Marzec M., Gimotty P., Crompton M.R., Wasik M.A.;
RT   "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine
RT   kinase in lymphocytes.";
RL   Am. J. Pathol. 168:1631-1641(2006).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF STAT3, AND ENZYME REGULATION.
RX   PubMed=16568091; DOI=10.1038/sj.onc.1209501;
RA   Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.;
RT   "Identification of STAT3 as a specific substrate of breast tumor
RT   kinase.";
RL   Oncogene 25:4904-4912(2006).
RN   [22]
RP   ENZYME REGULATION, AND MUTAGENESIS OF TRP-44.
RX   PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055;
RA   Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.;
RT   "Molecular dissection of the interaction between the SH3 domain and
RT   the SH2-Kinase Linker region in PTK6.";
RL   Biochem. Biophys. Res. Commun. 362:829-834(2007).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF STAT5B.
RX   PubMed=17997837; DOI=10.1186/bcr1794;
RA   Weaver A.M., Silva C.M.;
RT   "Signal transducer and activator of transcription 5b: a new target of
RT   breast tumor kinase/protein tyrosine kinase 6.";
RL   Breast Cancer Res. 9:R79-R79(2007).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF ARHGAP35.
RX   PubMed=18829532; DOI=10.1158/0008-5472.CAN-08-0997;
RA   Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L.,
RA   Settleman J., Chen R.H.;
RT   "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras
RT   and promote breast carcinoma growth, migration, and invasion.";
RL   Cancer Res. 68:7779-7787(2008).
RN   [25]
RP   INTERACTION WITH ADAM15.
RX   PubMed=18296648; DOI=10.1158/1541-7786.MCR-07-2028;
RA   Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M.,
RA   Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C.,
RA   Edwards D.R.;
RT   "Distinct functions of natural ADAM-15 cytoplasmic domain variants in
RT   human mammary carcinoma.";
RL   Mol. Cancer Res. 6:383-394(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [27]
RP   INTERACTION WITH ERBB2.
RX   PubMed=18719096; DOI=10.1073/pnas.0805009105;
RA   Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M.,
RA   Miller W.T., Muthuswamy S.K.;
RT   "Brk is coamplified with ErbB2 to promote proliferation in breast
RT   cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008).
RN   [28]
RP   INTERACTION WITH SFPQ.
RX   PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008;
RA   Lukong K.E., Huot M.E., Richard S.;
RT   "BRK phosphorylates PSF promoting its cytoplasmic localization and
RT   cell cycle arrest.";
RL   Cell. Signal. 21:1415-1422(2009).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003;
RA   Brauer P.M., Tyner A.L.;
RT   "Building a better understanding of the intracellular tyrosine kinase
RT   PTK6 - BRK by BRK.";
RL   Biochim. Biophys. Acta 1806:66-73(2010).
RN   [30]
RP   PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1.
RX   PubMed=20026641; DOI=10.1242/jcs.053264;
RA   Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y.,
RA   Asara J.M., Tyner A.L.;
RT   "Identification of beta-catenin as a target of the intracellular
RT   tyrosine kinase PTK6.";
RL   J. Cell Sci. 123:236-245(2010).
RN   [31]
RP   FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND
RP   CTNNB1.
RX   PubMed=21479203; DOI=10.1371/journal.pone.0014789;
RA   Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M.,
RA   Tyner A.L.;
RT   "The alternative splice variant of protein tyrosine kinase 6
RT   negatively regulates growth and enhances PTK6-mediated inhibition of
RT   beta-catenin.";
RL   PLoS ONE 6:E14789-E14789(2011).
RN   [32]
RP   STRUCTURE BY NMR OF 75-174.
RX   PubMed=15056653; DOI=10.1074/jbc.M313185200;
RA   Hong E., Shin J., Kim H.I., Lee S.T., Lee W.;
RT   "Solution structure and backbone dynamics of the non-receptor protein-
RT   tyrosine kinase-6 Src homology 2 domain.";
RL   J. Biol. Chem. 279:29700-29708(2004).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY,
RP   AND MUTAGENESIS OF LYS-219.
RX   PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121;
RA   Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R.,
RA   Gosu R.;
RT   "Crystal structure of the kinase domain of human protein tyrosine
RT   kinase 6 (PTK6) at 2.33 A resolution.";
RL   Biochem. Biophys. Res. Commun. 478:637-642(2016).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH
RP   INHIBITORS, AND CATALYTIC ACTIVITY.
RX   PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030;
RA   Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S.,
RA   Tyagi R., Gosu R.;
RT   "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel
RT   imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A
RT   resolution.";
RL   Biochem. Biophys. Res. Commun. 482:1289-1295(2017).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the
CC       regulation of a variety of signaling pathways that control the
CC       differentiation and maintenance of normal epithelia, as well as
CC       tumor growth. Function seems to be context dependent and differ
CC       depending on cell type, as well as its intracellular localization.
CC       A number of potential nuclear and cytoplasmic substrates have been
CC       identified. These include the RNA-binding proteins: KHDRBS1/SAM68,
CC       KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors:
CC       STAT3 and STAT5A/B and a variety of signaling molecules:
CC       ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates
CC       also with a variety of proteins that are likely upstream of PTK6
CC       in various signaling pathways, or for which PTK6 may play an
CC       adapter-like role. These proteins include ADAM15, EGFR, ERBB2,
CC       ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6
CC       promotes cellular differentiation and apoptosis. In tumors PTK6
CC       contributes to cancer progression by sensitizing cells to
CC       mitogenic signals and enhancing proliferation, anchorage-
CC       independent survival and migration/invasion. Association with
CC       EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and
CC       growth through enhancement of EGF-induced signaling via BTK/AKT
CC       and PI3 kinase. Contributes to migration and proliferation by
CC       contributing to EGF-mediated phosphorylation of
CC       ARHGAP35/p190RhoGAP, which promotes association with
CC       RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF
CC       stimulation resulted in phosphorylation of PNX/Paxillin by PTK6
CC       and activation of RAC1 via CRK/CrKII, thereby promoting migration
CC       and invasion. PTK6 activates STAT3 and STAT5B to promote
CC       proliferation. Nuclear PTK6 may be important for regulating growth
CC       in normal epithelia, while cytoplasmic PTK6 might activate
CC       oncogenic signaling pathways.
CC   -!- FUNCTION: Isoform 2 inhibits PTK6 phosphorylation and PTK6
CC       association with other tyrosine-phosphorylated proteins.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:12121988,
CC       ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680}.
CC   -!- ENZYME REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by
CC       SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by
CC       an association between the SH3 domain and the SH2-TK linker
CC       region. Interaction between Trp-184 within SH2-TK linker region
CC       and the catalytic domain appears essential for positive regulation
CC       of kinase activity. {ECO:0000269|PubMed:12121988,
CC       ECO:0000269|PubMed:15870689, ECO:0000269|PubMed:15961400,
CC       ECO:0000269|PubMed:16568091, ECO:0000269|PubMed:17822667}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=83 uM for ATP {ECO:0000269|PubMed:12121988};
CC         Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988};
CC   -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via
CC       SH3 and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2
CC       domains) with phosphorylated IRS4. Interacts with ADAM15.
CC       Interacts (via SH3 domain) with SFPQ. Interacts with EGFR and
CC       ERBB2. Interacts with STAP2. Interacts with PNX. Interacts with
CC       SFPQ. Interacts with PTK/ATK. Interacts with CTNNB1. {ECO:0000250,
CC       ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:10980601,
CC       ECO:0000269|PubMed:15539407, ECO:0000269|PubMed:15572663,
CC       ECO:0000269|PubMed:15870689, ECO:0000269|PubMed:18296648,
CC       ECO:0000269|PubMed:18719096, ECO:0000269|PubMed:19439179,
CC       ECO:0000269|PubMed:20026641, ECO:0000269|PubMed:8940083}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-1383632, EBI-1383632;
CC       Q5JST6:EFHC2; NbExp=5; IntAct=EBI-1383632, EBI-2349927;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-1383632, EBI-641062;
CC       Q8IW24:EXOC5; NbExp=3; IntAct=EBI-1383632, EBI-10171392;
CC       O14526:FCHO1; NbExp=3; IntAct=EBI-1383632, EBI-719823;
CC       Q13480:GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684;
CC       Q5VWX1:KHDRBS2; NbExp=3; IntAct=EBI-1383632, EBI-742808;
CC       P10721:KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503;
CC       Q04864:REL; NbExp=3; IntAct=EBI-1383632, EBI-307352;
CC       P23246:SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453;
CC       O00401:WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle.
CC       Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or
CC       KHDRBS3, within the nucleus. Nuclear localization in epithelial
CC       cells of normal prostate but cytoplasmic localization in cancer
CC       prostate.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13882-1; Sequence=Displayed;
CC       Name=2; Synonyms=ALT-PTK6, deltam5;
CC         IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067;
CC   -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon
CC       and high levels in small intestine and prostate, and low levels in
CC       some fetal tissues. Not expressed in breast or ovarian tissue but
CC       expressed in high percentage of breast and ovarian cancers. Also
CC       overexpressed in some metastatic melanomas, lymphomas, colon
CC       cancers, squamous cell carcinomas and prostate cancers. Also found
CC       in melanocytes. Not expressed in heart, brain, placenta, lung,
CC       liver, skeletal muscle, kidney and pancreas. Isoform 2 is present
CC       in prostate epithelial cell lines derived from normal prostate and
CC       prostate adenocarcinomas, as well as in a variety of cell lines.
CC       {ECO:0000269|PubMed:12833144, ECO:0000269|PubMed:15509496,
CC       ECO:0000269|PubMed:16651629, ECO:0000269|PubMed:9185712}.
CC   -!- DOMAIN: The SH3 domain plays a major role in substrate
CC       interactions. The SH2 domain of PTK6 plays a role in protein-
CC       protein interactions, but is likely more important for the
CC       regulation of catalytic activity.
CC   -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to
CC       an increase of kinase activity. Tyr-447 binds to the SH2 domain
CC       when phosphorylated and negatively regulates kinase activity.
CC       {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988,
CC       ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}.
CC   -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket.
CC       {ECO:0000269|PubMed:27993680}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X78549; CAA55295.1; -; mRNA.
DR   EMBL; U61412; AAC34935.1; -; Genomic_DNA.
DR   EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; AK315232; BAG37660.1; -; mRNA.
DR   EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA.
DR   EMBL; AL121829; CAC15525.1; -; Genomic_DNA.
DR   EMBL; BC035843; AAH35843.1; -; mRNA.
DR   CCDS; CCDS13524.1; -. [Q13882-1]
DR   CCDS; CCDS74750.1; -. [Q13882-2]
DR   PIR; S49016; S49016.
DR   RefSeq; NP_001243287.1; NM_001256358.1. [Q13882-2]
DR   RefSeq; NP_005966.1; NM_005975.3. [Q13882-1]
DR   UniGene; Hs.51133; -.
DR   PDB; 1RJA; NMR; -; A=75-174.
DR   PDB; 2KGT; NMR; -; A=1-72.
DR   PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446.
DR   PDB; 5DA3; X-ray; 1.70 A; A=185-446.
DR   PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446.
DR   PDBsum; 1RJA; -.
DR   PDBsum; 2KGT; -.
DR   PDBsum; 5D7V; -.
DR   PDBsum; 5DA3; -.
DR   PDBsum; 5H2U; -.
DR   ProteinModelPortal; Q13882; -.
DR   SMR; Q13882; -.
DR   BioGrid; 111720; 23.
DR   DIP; DIP-39785N; -.
DR   IntAct; Q13882; 29.
DR   MINT; MINT-1494499; -.
DR   STRING; 9606.ENSP00000217185; -.
DR   BindingDB; Q13882; -.
DR   ChEMBL; CHEMBL4601; -.
DR   DrugBank; DB05294; Vandetanib.
DR   GuidetoPHARMACOLOGY; 2182; -.
DR   iPTMnet; Q13882; -.
DR   PhosphoSitePlus; Q13882; -.
DR   BioMuta; PTK6; -.
DR   DMDM; 8928302; -.
DR   MaxQB; Q13882; -.
DR   PaxDb; Q13882; -.
DR   PeptideAtlas; Q13882; -.
DR   PRIDE; Q13882; -.
DR   DNASU; 5753; -.
DR   Ensembl; ENST00000217185; ENSP00000217185; ENSG00000101213. [Q13882-2]
DR   Ensembl; ENST00000542869; ENSP00000442460; ENSG00000101213. [Q13882-1]
DR   GeneID; 5753; -.
DR   KEGG; hsa:5753; -.
DR   UCSC; uc002yfg.5; human. [Q13882-1]
DR   CTD; 5753; -.
DR   DisGeNET; 5753; -.
DR   GeneCards; PTK6; -.
DR   HGNC; HGNC:9617; PTK6.
DR   HPA; CAB032952; -.
DR   HPA; HPA036070; -.
DR   HPA; HPA036071; -.
DR   MIM; 602004; gene.
DR   neXtProt; NX_Q13882; -.
DR   OpenTargets; ENSG00000101213; -.
DR   PharmGKB; PA33960; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOGENOM; HOG000233858; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; Q13882; -.
DR   KO; K08894; -.
DR   OMA; VRHYKIW; -.
DR   OrthoDB; EOG091G0596; -.
DR   PhylomeDB; Q13882; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing.
DR   Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   Reactome; R-HSA-8849472; PTK6 Down-Regulation.
DR   Reactome; R-HSA-8849473; PTK6 Expression.
DR   Reactome; R-HSA-8849474; PTK6 Activates STAT3.
DR   Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization.
DR   SignaLink; Q13882; -.
DR   SIGNOR; Q13882; -.
DR   EvolutionaryTrace; Q13882; -.
DR   GeneWiki; PTK6; -.
DR   GenomeRNAi; 5753; -.
DR   PRO; PR:Q13882; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000101213; -.
DR   CleanEx; HS_PTK6; -.
DR   Genevisible; Q13882; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0060575; P:intestinal epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl.
DR   GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0009968; P:negative regulation of signal transduction; TAS:Reactome.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; TAS:Reactome.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0042503; P:tyrosine phosphorylation of Stat3 protein; IDA:UniProtKB.
DR   GO; GO:0042506; P:tyrosine phosphorylation of Stat5 protein; IDA:UniProtKB.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Complete proteome; Cytoplasm; Kinase; Membrane; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; SH2 domain;
KW   SH3 domain; Transferase; Tyrosine-protein kinase.
FT   CHAIN         1    451       Protein-tyrosine kinase 6.
FT                                /FTId=PRO_0000088133.
FT   DOMAIN       11     72       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN       78    170       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      191    445       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     197    205       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      171    190       Linker.
FT   ACT_SITE    312    312       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     219    219       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000305|PubMed:27480927,
FT                                ECO:0000305|PubMed:27993680}.
FT   MOD_RES      13     13       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES      61     61       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES      66     66       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES     114    114       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000269|PubMed:12121988}.
FT   MOD_RES     342    342       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES     351    351       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES     447    447       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10913193}.
FT   VAR_SEQ      78    134       WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSV
FT                                RDTQAVRHYKIWRRAG -> AGHAGCAALQDLAACRGPAAP
FT                                ERGGVLPQPARACELPQGPEPVPRPAAGRALPEARA (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:9333026}.
FT                                /FTId=VSP_042066.
FT   VAR_SEQ     135    451       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:9333026}.
FT                                /FTId=VSP_042067.
FT   VARIANT      16     16       L -> F (in a renal papillary sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041760.
FT   VARIANT     436    436       A -> T (in dbSNP:rs56145017).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041761.
FT   MUTAGEN      44     44       W->A: Strong decrease in STAP2
FT                                phosphorylation. Markedly decreased
FT                                interaction between SH3 domain the linker
FT                                region. {ECO:0000269|PubMed:10980601,
FT                                ECO:0000269|PubMed:17822667}.
FT   MUTAGEN      66     66       Y->A: Decrease in STAP2 phosphorylation.
FT                                {ECO:0000269|PubMed:10980601}.
FT   MUTAGEN     105    105       R->L: Decrease in STAP2 phosphorylation.
FT                                {ECO:0000269|PubMed:10980601}.
FT   MUTAGEN     184    184       W->A: Abrogates interaction between PTK6-
FT                                domain kinase and PTK6-linker. Abrogates
FT                                autophosphorylation and phosphorylation
FT                                of KHDRBS1.
FT                                {ECO:0000269|PubMed:15961400}.
FT   MUTAGEN     219    219       K->M: Abolishes kinase activity and cell
FT                                transformation, and phosphorylation of
FT                                STAP2. {ECO:0000269|PubMed:10980601,
FT                                ECO:0000269|PubMed:15471878,
FT                                ECO:0000269|PubMed:8940083}.
FT   MUTAGEN     219    219       K->R: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:27480927}.
FT   MUTAGEN     342    342       Y->A: 3-fold lower specific kinase
FT                                activity. Decreased, but still
FT                                significant, autophosphorylation.
FT                                Decreased, but still significant,
FT                                autophosphorylation; when associated with
FT                                A-447. {ECO:0000269|PubMed:12121988}.
FT   MUTAGEN     447    447       Y->F: Decrease in transforming potential
FT                                and increase in the kinase activity
FT                                level. Decreased, but still significant,
FT                                autophosphorylation; when associated with
FT                                A-342. {ECO:0000269|PubMed:12121988,
FT                                ECO:0000269|PubMed:15471878,
FT                                ECO:0000269|PubMed:8940083}.
FT   STRAND       12     14       {ECO:0000244|PDB:2KGT}.
FT   STRAND       35     40       {ECO:0000244|PDB:2KGT}.
FT   STRAND       45     50       {ECO:0000244|PDB:2KGT}.
FT   STRAND       56     62       {ECO:0000244|PDB:2KGT}.
FT   TURN         64     66       {ECO:0000244|PDB:2KGT}.
FT   STRAND       67     70       {ECO:0000244|PDB:2KGT}.
FT   HELIX        85     92       {ECO:0000244|PDB:1RJA}.
FT   STRAND      102    106       {ECO:0000244|PDB:1RJA}.
FT   STRAND      108    112       {ECO:0000244|PDB:1RJA}.
FT   STRAND      114    118       {ECO:0000244|PDB:1RJA}.
FT   STRAND      125    131       {ECO:0000244|PDB:1RJA}.
FT   STRAND      133    135       {ECO:0000244|PDB:1RJA}.
FT   STRAND      137    140       {ECO:0000244|PDB:1RJA}.
FT   STRAND      143    147       {ECO:0000244|PDB:1RJA}.
FT   HELIX       148    157       {ECO:0000244|PDB:1RJA}.
FT   STRAND      162    164       {ECO:0000244|PDB:1RJA}.
FT   HELIX       188    190       {ECO:0000244|PDB:5DA3}.
FT   STRAND      191    200       {ECO:0000244|PDB:5DA3}.
FT   STRAND      203    210       {ECO:0000244|PDB:5DA3}.
FT   TURN        211    213       {ECO:0000244|PDB:5DA3}.
FT   STRAND      214    221       {ECO:0000244|PDB:5DA3}.
FT   HELIX       223    225       {ECO:0000244|PDB:5DA3}.
FT   HELIX       233    240       {ECO:0000244|PDB:5DA3}.
FT   STRAND      250    254       {ECO:0000244|PDB:5DA3}.
FT   STRAND      256    264       {ECO:0000244|PDB:5DA3}.
FT   HELIX       272    277       {ECO:0000244|PDB:5DA3}.
FT   TURN        281    283       {ECO:0000244|PDB:5DA3}.
FT   HELIX       286    305       {ECO:0000244|PDB:5DA3}.
FT   HELIX       315    317       {ECO:0000244|PDB:5DA3}.
FT   STRAND      318    320       {ECO:0000244|PDB:5DA3}.
FT   HELIX       322    324       {ECO:0000244|PDB:5DA3}.
FT   STRAND      326    328       {ECO:0000244|PDB:5DA3}.
FT   HELIX       333    336       {ECO:0000244|PDB:5DA3}.
FT   HELIX       339    343       {ECO:0000244|PDB:5DA3}.
FT   HELIX       345    348       {ECO:0000244|PDB:5DA3}.
FT   HELIX       349    352       {ECO:0000244|PDB:5DA3}.
FT   HELIX       356    361       {ECO:0000244|PDB:5DA3}.
FT   HELIX       366    380       {ECO:0000244|PDB:5DA3}.
FT   TURN        381    384       {ECO:0000244|PDB:5DA3}.
FT   HELIX       393    401       {ECO:0000244|PDB:5DA3}.
FT   HELIX       414    423       {ECO:0000244|PDB:5DA3}.
FT   HELIX       428    430       {ECO:0000244|PDB:5DA3}.
FT   HELIX       434    442       {ECO:0000244|PDB:5DA3}.
SQ   SEQUENCE   451 AA;  51834 MW;  CDCAC0EE242E1BD7 CRC64;
     MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG
     YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD
     TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH
     WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK
     KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM
     CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS
     RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM
     LTCWCRDPEQ RPCFKALRER LSSFTSYENP T
//
